| Metric / Grade Dimension | Grade | Score | Evidence & Rationale | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 78 | Mid-cap biotech with solid dividend yield (2.63%), modest price momentum (+39.6% YTD), and analyst consensus "Buy." Offset by elevated P/E (110x), negative EPS growth (-13.47% YoY), and weak profitability flags. Valuation compression vs. fundamentals limits upside. | 6–12 months |
| SA Quality/Value Composite | B | 72 | Strong revenue growth (+9.5% YoY) and established dividend track record ($6.60 DPS, 2.63% yield). Forward P/E of 15.4x suggests normalized valuation in context of biotech peers. However, current trailing P/E of 110x and weak near-term profitability flags ("strong_profitability": false) dampen score. | 3–6 months |
| Zacks Earnings Momentum | C+ | 68 | EPS contraction of 13.47% YoY is material headwind. Forward guidance implied by forward P/E 15.4x suggests management expects normalized earnings recovery. No real-time earnings revision data in live feed; caution warranted pending Q2 2026 detailed results. | 1–3 months |
| Institutional & Smart Money Flow | B | 75 | 32–40 analysts covering ABBV with consensus "Buy" and average price target of $252.90–$266.89 (1.4%–2.9% above current $263.30). Buy percentage consensus 79% (bullish). Piper Sandler raised target to $289; Citi neutral at $240. Broad coverage suggests institutional interest intact. | 6–12 months |
| Growth Sustainability & Moat | B– | 70 | Revenue growth at +9.5% is respectable but modest for biotech. Pipeline strength in Skyrizi, Rinvoq, and Neuroscience (Botox, Ubrelvy, Qulipta) provides product diversification. However, Humira biosimilar erosion and competitive pressures in aesthetics limit long-term pricing power. Hyper-growth flag contradicts weak profitability signal—potential signal of early-stage asset appreciation vs. cash generation. | 6–12 months |
| Valuation & Safety (Pre-Penalty) | C | 62 | Trailing P/E of 110x is severely elevated relative to market and biotech peer median (~20–35x). Forward P/E of 15.4x implies steep near-term earnings recovery expectation. EPS yield of ~0.78% (1/110) vs. dividend yield of 2.63% suggests market undervaluing near-term cash returns. Beta of 0.26 signals defensive positioning; drawdown risk limited. | 1–3 months |
| Penalty Overlay | — | −8 | High valuation flag (110x trailing P/E) warrants −5 to −10 point penalty. Strong profitability flag is false, indicating near-term margin pressure: −3 to −5 points. Combined penalty: −8 points applied to final score. | 1–3 months |
| CONFIDENCE SCORE | A– | 85 | Broad analyst coverage (32–40 firms), consistent messaging across major houses, live price data current to July 30 2026, and transparent SEC filing disclosure. Low beta (0.26) reduces surprise volatility. Primary uncertainty: timing of Humira biosimilar impact and Skyrizi market penetration post-2026. | 6–12 months |
| Volatility & Drawdown Risk | A | 88 | Beta of 0.26 is among lowest in biotech—approximately 74% less volatile than S&P 500. 52-week range of $187.62–$266.92 reflects 42.2% amplitude, well-contained. Dividend cushion (2.63% yield) provides capital return floor. Low systematic risk profile supports core holdings. | 6–12 months |
| Crowding Risk Flag | B | 72 | 79% buy consensus and 31 major houses maintaining coverage indicate crowding into bullish positioning. However, spread of price targets ($200–$328, wide variance) and dissenting Neutral views (Citi at $240) suggest genuine debate remains. Not at maximum consensus compression risk (which would be >90% buy). | 3–6 months |
AbbVie competes within the diversified biologics/pharma space (Biotechnology sector per GICS). Peer set spans Biogen (higher growth, steeper valuation), Regeneron (premium valuation, strong pipeline), and dividend-focused peers like Johnson & Johnson (higher dividend yield, lower growth). ABBV's positioning: stable revenue growth (+9.5%), defensive beta (0.26), attractive dividend (2.63%), but temporary EPS pressure (−13.47% YoY) and elevated trailing valuation. Within the mid-cap biotech cohort, ABBV trades as a "quality dividend hybrid" rather than pure-play growth or value.
According to 31 analysts, AbbVie has a consensus price target of $266.89 , which is 2.90% higher than the current stock price, with the lowest at $200 and the highest at $328 . The broad 64% range between low and high targets reflects genuine analytical uncertainty around Humira biosimilar timing and new product penetration, though the cluster around $250–$270 indicates central bullish conviction. Recent target actions underscore confidence in neuroscience and dermatology segments.
ABBV Systematic Research
AbbVie Inc presents a distinctive profile within biotechnology, characterized by exceptional return on equity of 95.59% against a heavily leveraged capital structure with debt-to-equity of 20.19. The company's current price of $250.94 positions near the upper boundary of its 52-week range ($187.62–$267.47), while the beta of 0.27 indicates significantly lower volatility than broader equity markets.
Systematic screening highlights several operational strengths:
- Revenue momentum: Year-over-year revenue growth of 9.5% demonstrates market share expansion across the immunology and oncology portfolios, supporting the $443.4 billion market capitalization
- Margin efficiency: Gross margin of 72.03% reflects strong pricing power in specialty pharmaceuticals, though operating margin compression to 24.41% suggests elevated R&D and commercialization investments
- Return profile: ROE of 95.59% substantially exceeds industry norms, though this metric reflects the aggressive financial engineering inherent in the 20.19 debt-to-equity ratio
The fundamental model flags material considerations. The price-to-book ratio of 94.44 and trailing P/E of 122.88 reflect premium valuation multiples relative to historical biotechnology sector averages. Year-over-year EPS contraction of -13.47% to $2.05 suggests earnings normalization following patent cliff dynamics. The current ratio of 0.67 indicates potential near-term liquidity constraints requiring ongoing capital market access.
Research perspective relative to peers AMGN and Korean biotechnology comparables positions AbbVie as a higher-leverage, premium-multiple play trading on franchise durability rather than current earnings power. The systematic screening framework emphasizes balance sheet structure as the defining characteristic separating this name from comparable large-cap biotechnology holdings.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.